Targeted for destruction: The molecular basis for development of novel therapeutic strategies in renal cell cancer

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 410-412

  Srinivasan, Ramaprasad ^a   Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERYTHROPOIETIN; GLUCOSE TRANSPORTER 1; IMATINIB; INTERLEUKIN 2; PLATELET DERIVED GROWTH FACTOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SORAFENIB; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; ANTINEOPLASTIC AGENT; CASPASE; ENZYME INHIBITOR;

APOPTOSIS; CANCER INCIDENCE; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; MITOCHONDRION; NOTE; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, RENAL CELL; CASPASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MITOCHONDRIA;

EID: 14544282903     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.907     Document Type: Editorial

References (21)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Chow WH, Devesa SS, Warren JL, et al: Rising incidence of renal cell cancer in the United States. JAMA 281:1628-1631, 1999
3. Linehan WM, Yang JC, Bates SE: Cancer of the kidney, in DeVita SE, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 7). Philadelphia, PA, Lippincott Williams and Wilkins, 2004
4. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
5. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
6. Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol 170:2163-2172, 2003
7. Latif F, Duh FM, Gnarra J, et al: Von Nippel-Lindau syndrome: Cloning and identification of the plasma membrane Ca(++)-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res 53:861-867, 1993
8. Zbar B, Tory K, Merino M, et al: Hereditary papillary renal cell carcinoma. J Urol 151:561-566, 1994
9. Schmidt L, Duh FM, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73, 1997
10. Toro JR, Nickerson ML, Wei MH, et al: Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73:95-106, 2003
11. Schmidt LS, Warren MB, Nickerson ML, et al: Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 69:876-882, 2001
12. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
13. Motzer RJ, Rini BI, Michaelson MD, et al: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol 22:382s, 2004 (abstr 4500)
14. Hainsworth JD, Sosman JA, Spiger DR: Phase Il trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Proc Am Soc Clin Oncol 22:382, 2004 (abstr 4502)
15. Ratain MJ, Flaherty KT, Stadler WM, et al: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Proc Am Soc Clin Oncol 22:382s, 2004 (abstr 4501)
16. Mizutani Y, Hiroyuki N, Yamamoto K, et al: Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 23:448-454, 2005
17. Salvesen GS, Duckett CS: IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410, 2002
18. Yang L, Cao Z, Yan H, et al: Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res 63:6815-6824, 2003
19. Ramp U, Krieg T, Caliskan E, et al: XIAP expression is an independent prognostic marker in clear-cell renal carcinomasl. Hum Pathol 35:1022-1028, 2004
20. Schimmer AD, Welsh K, Pinilla C, et al: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5:25-35, 2004
21. Arnt CR, Chiorean MV, Heldebrant MP, et al: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAPI in situ. J Biol Chem 277:44236-44243, 2002